verified SJR 0,61 · Q3

United States · Mary Ann Liebert Inc.

workspace_premium Q3 — Genetics (clinical) lock Subscription

Human gene therapy. Clinical development

Human gene therapy. Clinical development is a journal indexed in SJR in Genetics (clinical) with an H index of 31. It has a price of 2395 €. It has an SJR impact factor of 0,61 and it has a best quartile of Q3. It has an SJR impact factor of 0,61.

ISSN: 2324-8637

Publisher: Mary Ann Liebert Inc.

Category: Genetics (clinical)

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,61 Q3

H-index 31

Acceptance rate pie_chart

36%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

SJR Impact

0,61

H-index

Docs (year)

Docs 3y

Total refs

Cites 3y

Citable 3y

Cites/Doc 2y

Ref/Doc

0.0

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide

Varinostat Alters Gene Expression Profiles in Aortic Tissues from ApoE-/-Mice

Establishing a Large-Animal Model for In Vivo Reprogramming of Bile Duct Cells into Insulin-Secreting Cells to Treat Diabetes

Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview

Dystrophin gene replacement and gene repair therapy for Duchenne muscular dystrophy in 2016

Duchenne Muscular Dystrophy Gene Therapy in the Canine Model

Duchenne muscular dystrophy gene therapy in the canine model

Dog Models for Blinding Inherited Retinal Degenerations

Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?

Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy

Advancing Translational Research Through the NHLBI Gene Therapy Resource Program (GTRP)

SHOW MORE ARTICLES

Adenovirus-Mediated FKHRL1/TM Sensitizes Melanoma Cells to Apoptosis Induced by Temozolomide

"PULSED" versus "CONTINUOUS" application of the prodrug 5-FC for enhancing oncolytic effectiveness of a measles vaccine virus armed with a suicide gene

AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees

AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees

A review of gene therapy in canine and feline models of lysosomal storage disorders

A Preclinical Study in Rhesus Macaques for Cystic Fibrosis to Assess Gene Transfer and Transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System

A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients

A Multicenter, Single-Blind, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of a Cell-Mediated Gene Therapy in Degenerative Knee Arthritis Patients

A Multicenter, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Cell and Gene Therapy in Knee Osteoarthritis Patients

A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow

A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB

A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB

FAQs

Human gene therapy. Clinical development has an SJR of 0,61 (best quartile Q3) in the CountryOfPapers database.

Immediate OA APC is 2395 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Human gene therapy. Clinical development is 36%.

Human gene therapy. Clinical development

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Human gene therapy. Clinical development?

What is the APC / publication cost?

What is the acceptance rate?